TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
|
|
- Oswin O’Brien’
- 5 years ago
- Views:
Transcription
1 TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
2 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant TB Nutrition Support
3 BACKGROUND Globally, one third of the world is infected with TB, though roughly 90-95% of people without HIV will never go on to develop active disease Tuberculosis is the commonest opportunistic infection in people with HIV in Sub- Saharan Africa & can present at any CD4 count TB is the primary cause of morbidity & mortality in patients with HIV & difficult to diagnose in patients with HIV Sputum smears are usually ve in active disease & patients often have atypical clinical & radiographic presentations HIV infected patients are more likely to present with extra pulmonary TB TB can occur at any point in the course of progression of HIV infection & the risk of developing TB rises sharply with worsening immune status
4 BACKGROUND (CONTD) A person infected with HIV has 10 times increased risk of developing TB With a co-infection rate ranging from 64% to 80% and the emergence of MDR-TB in the country, a huge strain has been put on the existing health infrastructure WHO estimates that HIV contributes to 68% of deaths in TB patients on treatment (Increased from 10% in 1995 to 13.5% in 2000) Mortality is 2-4 times higher, 6-39% in SSA Early diagnosis & effective treatment of TB among HIV infected patients are critical for curing TB, minimizing the -ve effects of TB on the course of HIV & interrupting the transmission of M. Tuberculosis to other persons in the community
5 Incidence per 100,000 per year Global incidence of tuberculosis AFR high HIV AFR low HIV 200 So East Asia World West. Pacific 100 East. Medit. East. Europe Lat. America 0 Cent. Euro, Est Market
6 THE PROBLEM
7 ESSENTIAL TB FIGHTING ACTIVITIES FOR HIV PROGRAMS The 3 I s Intensive case Finding INH Prophylaxis Therapy Infection Control
8 Intensified Case Finding(ICF): To increase the early identification of TB disease Provision of Isoniazid Preventive Therapy (IPT): To reduce the risk of TB to those in whom active TB disease can be excluded Infection Control practices(ic): To reduce the likelihood of exposure to TB bacilli, in clinical, congregate settings and in the community
9 SCREENING FOR TB
10 1. INITIAL ASSESSMENT OF HIV STATUS IN TB PATIENTS Be offered by trained counselors & health care workers HIV pre-test counseling Do Rapid test, if +ve, draw blood for CD4 count & encourage partner testing in household & children Post-test counseling & give information on reducing risky sexual behaviour Open TB card & enroll into HIV care & Treatment if HIV +ve If ve, repeat test after 3 months & Health educate on how to remain ve If Indeterminate, do tie-braker test using Rapid test or ELISA
11 KEY FEATURES SUGGESTIVE OF ACTIVE TUBERCULOSIS Close contact with an active case of TB; especially if smearpositive Symptoms suggestive of TB Cough Fever: Temperature > 38 degrees Celsius for > 2 weeks (after common causes such as pneumonia have been excluded) Night sweats Weight loss or failure to thrive Sputum production, dyspnoea, haemoptysis, etc (not part of routine symptom screen, but if a patient reports, this should raise the provider s suspicion for TB)
12 PHYSICAL SIGNS HIGHLY SUGGESTIVE OF TB Pulmonary crackles, wheezing, decreased breath sounds Extra pulmonary Manifestations: Non-painful enlarged cervical lymph nodes with or without fistula formation Meningitis not responding to the usual antibiotic treatment Distended abdomen with ascitis Non-painful enlarged joints Documented weight loss or failure to gain weight
13 Positive tuberculin skin test Not routinely available in Lesotho An induration of 5 mm or more in diameter is significant CXR suggestive of TB Enlarged hilar or subcarinal lymph nodes Persistent opacification in the lung which does not improve after a course of antibiotics Miliary pattern Large pleural effusions Apical infiltrates with cavity formation
14 TREATMENT Initiate patients on ATT as soon as a diagnosis is made & enroll in TB register TB treatment regimens should include four drugs Children with TB can be given Ethambutol, recommended in Lesotho given the high rates of drug resistance (> 3%) Initiate ART within 2 to 4 wks after starting ATT due to high mortality rate & risk of OIs
15 NEW RECOMMENDATIONS FOR INITIATION OF FIRST-LINE ART IN ADULTS/ADOLESCENTS ALREADY ON ANTI-TB TREATMENT Start ART in all HIV-infected individuals with active TB irrespective of the CD4 cell count. Start TB treatment first followed by ART within 2-4 weeks of ATT commencement. Use Efavirenz (EFV) as the preferred NNRTI in patients on TB treatment.
16 INITIATING FIRST-LINE ART IN CHILDREN ALREADY ON ATT Any HIV-infected child with active TB disease should begin TB treatment immediately and start ART within 2-4 of TB therapy irrespective of CD4 count or clinical stage For concurrent HAART and ATT: Children < 3 years of age: AZT or d4t + 3TC + NVP (at maximum target dose of 200mg/m 2 ) Children > 3 years of age: AZT or d4t + 3TC + EFV NVP although interact with Rifampicin, it is recommended due to its demonstrated clinical efficacy as well as current familiarity with its use among health care providers Abacavir is not recommended due to the known inferior potency of triple NRTI therapy and the potential difficulty in diagnosing hypersensitivity reaction especially in rural settings.
17 DEVELOPING TUBERCULOSIS WHILE ON ART Adults and children > 3 years and > 10 kg who are on Nevirapine based regimens must be switched to Efavirenz. Children < 3 years of age and < 10 kg can be maintained on a Nevirapine- based regimen LPV/r and other PIs have significant interactions with rifampicins and should not routinely be used together If a patient is on LPV/r, consider adding Ritonavir (RTV) in a ratio of 1:1 (LPV: RTV) to achieve the full therapeutic dose of RTV. A superboosted Kaletra can be an alternative in adults Due to difficulty of taking ATT & ART as well as the risk of developing drug resistance, patients should receive (Directly Observed Therapy) DOT during the course of their TB Treatment
18 ADVERSE EFFECTS overlapping toxicities exists between ATT and ART closely monitor co-infected patients on dual therapy (i.e. monthly ALT) Give pyridoxine (vitamin B 6) as a routine part of ATT in co-infected patients because of peripheral neuropathy due to d4t, INH, Patient on ATT as much as possible should not receive d4t as part of their ART regimen. Give Pyridoxine 25 mg daily for adults and Children > 3 years 12.5 mg daily for children < 3 years
19 OVERLAPPING SIDE EFFECTS/ADVERSE REACTIONS TO 1 ST LINE ANTI TB & ART DRUGS POSSIBLE CAUSES SIDE EFFECTS ANTI TB DRUGS ARV DRUGS SKIN RASH PZA, RIF, INH NVP, EFV, ABC NAUSEA, VOMIITING PZA, RIF, RBT, INH AZT, RTV HEPATITS PZA, RIF, RBT, INH NVP, PIs LEUKOPENIA, ANEAMIA RBT, RIF AZT
20 2. ISONIAZID PROPHYLAXIS THERAPY (IPT) IPT is beneficial in preventing morbidity and mortality from TB. Isoniazid prophylaxis should be administered to HIV positive adults. The prophylaxis should also be administered to eligible PLWHIV. It should be offered regardless of ART To avoid the risk of treating TB with a single agent, active TB must first be ruled out before administering IPT: TB exposed, HIV-infected children should be given isoniazid mg/kg daily for 6 months Adults: 5 mg/kg/day (up to maximum of 300 mg daily) Children: mg/kg/day (up to maximum of 300 mg daily)
21 IPT PROTOCOL Before offering INH prophylaxis, active TB must be ruled out clinically For children > 5 years, IPT should be administered if a child has been in contact with active Pulmonary Tuberculosis patients whether the child is HIV positive or negative All HIV positive adults patients and children >12months should receive IPT if they are well and active TB has been ruled out or a full course of TB treatment if active TB is suspected IPT prophylaxis for children < 15 years who are HIVinfected and TB-exposed
22 Isoniazid: mg/kg daily for 6 months Pyridoxine (to prevent peripheral neuropathy): 12.5 mg daily for 6 months for children < 3 years 25 mg daily for 6 months for children 3 years and above All HIV-infected children exposed to TB through household contacts but with no evidence of active disease, should begin Isoniazid Preventive Therapy (IPT). Children >12 months of age should receive 6 months of IPT as part of a comprehensive package of HIV care irrespective of TB exposure ALT assay should be done as a baseline test for everyone
23 Infants <12 months HIV infected and TB exposed should receive IPT and followed clinically as part of a comprehensive package of HIV care. However, children in this age range who are not TB exposed should not receive IPT INH 300 mg is administered once daily in adults
24 The risk of hepatitis increases with increased age, alcoholism, prior liver disease, pregnancy and concurrent Rifampicin use (2%). Monitored for clinical evidence of hepatitis, other side effects; TB symptoms; and adherence to the prophylactic regimen. Monthly ALT assays should be done in patients with baseline liver disease and in cases where abnormal ALT levels develop during treatment Discontinue INH in case: ALT levels increase to >5 Upper Limit of Normal (ULN) The patient develops symptoms of Hepatitis The patient develops symptoms of TB
25 If symptoms of TB occur culture and Drug Susceptibility Test (DST) should be systematically performed
26 3.INFECTION CONTROL MEASURES Control measures include: (Screen, Educate, Separate, Triage, Investigate) Give priority to TB patients & TB suspects at OPD Health educate on cough hygiene (cover mouth & nose with tissue & dispose safely) Proper ventilation of waiting areas & consultation rooms ( Windows should remain opened) Do not sit directly opposite TB patients/tb suspects Do not face the direction of the wind Educate TB supporters Health workers should use N 95 Mask Educate on nutrition
27 DRUG-RESISTANT TB Drug-resistant forms of TB (such as MDR-TB and XDR-TB) are commoner among HIV infected people patient not clinically or bacteriologically responding to antituberculosis therapy after 2 months should have sputum sent for culture and drug susceptibility testing (DST) or rapid molecular assay using GeneXpert
28 NUTRITIONAL SUPPORT Both TB & HIV are wasting diseases and patients have been shown to have improved outcomes when nutritional support is provided. Health centres should pair with relevant partner organizations for provision of actual food supplements to patients
29 Kea Leboha
TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationGary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!
Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!! DECLARATION No relevant conflicts of interest to declare OVERVIEW Burden of disease & epidemiology Pathogenesis (not
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationUpdates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013
Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationJames Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital
James Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital Paediatric HIV Infection Symposium, August 21, 2010, Red Cross Children s Hospital Overview of talk The 2010 paediatric guidelines
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationOverview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
More informationThe New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations
Workshop to accelerate the implementation of the Three Is for HIV/TB and earlier initiation of ART in Southern Africa, March 14-18, 2011, Johannesburg, South Africa. The New WHO guidelines on intensified
More informationTB in Children. Rene De Gama Block 10 Lectures 2012
TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationThe SAARC Regional Programme Guidelines of Diagnosis & Management of Pediatric Tuberculosis (TB) 2017
The SAARC Regional Programme Guidelines of Diagnosis & Management of Pediatric Tuberculosis (TB) 2017 SAARC Tuberculosis and HIV/AIDS Centre (STAC) Thimi, Bhaktapur P.O.Box No.: 9517, Kathmandu, Nepal.
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationTuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013
Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013 1 TB in Toronto - risk groups Diagnosis of active TB LTBI diagnosis and management Infection control 2 TB in Toronto Case
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric Tuberculosis: Infection Control, Source Case and Contact Investigation Ana M. Alvarez, M.D. Associate Professor Division of Pediatric Infectious Diseases and Immunology University
More informationTuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
More informationApproach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
More informationDRAFT. Comprehensive Approach. to the Management of TB/HIV Co-Infection
UNIT 3 Comprehensive Approach to the Management of TB/HIV Co-Infection HIV CURRICULUM PARTICIPANT S MANUAL PARTNERS IN HEALTH UNIT 3 BACKGROUND HIV and tuberculosis (TB) are both dangerous diseases, but
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationDifference of opinion? Michelle Moorhouse 24 Sep 2014
Difference of opinion? Michelle Moorhouse 24 Sep 2014 Meet NN 52 years, female Nurse in pre-art clinic Referred Feb 2012 by dermatologist History of severe reactions to ART Erythema and bullous eruptions
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationIntensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite
Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.
More informationUPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE
UPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE 3/13/2013 Contents Group Work Instructions... 2 PMTCT... 3 Case Study 1: Unbooked Pregnant Women... 3 Case Study 2: First ANC
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationDr Francis Ogaro MTRH ELDORET
Dr Francis Ogaro MTRH ELDORET TB in children often severe, disseminated and can progress rapidly and with poor outcome TB diagnosis in children has relied on clinical, imaging, microscopy and TST findings.
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationADDRESSING MDR TB IN THE CONTEXT OF HIV: Lessons from Lesotho. Dr Hind Satti PIH Lesotho Director MDR-TB program
ADDRESSING MDR TB IN THE CONTEXT OF HIV: Lessons from Lesotho Dr Hind Satti PIH Lesotho Director MDR-TB program TB Situation in Lesotho 12,275 TB new cases notified in 2007 Estimated prevalence of 544
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationAnri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town Since March 2008 26 700 Queries to date 450 Queries per month South Africa:
More informationTreatment of MDR-TB in high HIV- prevalence settings. Hind Satti, M.D. PIH-Lesotho October 20, 2008
Treatment of MDR-TB in high HIV- prevalence settings Hind Satti, M.D. PIH-Lesotho October 20, 2008 Early outcomes of MDR-TB treatment Retrospective cohort analysis Registered between July 21, 2007 and
More informationIsoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children. Réghana Taliep
Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children Réghana Taliep Background Tuberculosis (TB) is a common complication and leading cause of death in HIV infection HIV is the strongest
More informationGUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG PEOPLE LIVING WITH HIV AND SILICOSIS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG PEOPLE LIVING WITH HIV AND SILICOSIS IN SOUTH AFRICA Page 1 of 17 TABLE OF CONTENT 1 BACKGROUND... 4 2 TB, HIV AND SILICOSIS... 4 2.1 TB PREVENTIVE
More informationDrug-sensitive and drugresistant
CHAPTER 7 87 Drug-sensitive and drugresistant tuberculosis Tuberculosis Types of active TB disease Five I s to reduce the burden of TB in PLHIV Clinical presentation of extrapulmonary TB Evaluating for
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More information10. TB and HIV Infection
10. TB and HIV Infection The management of patients with TB and HIV infection is complex, requiring management by a multidisciplinary team which includes physicians with expertise in the treatment of both
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationManagement of HIV Infected Children and Adolescents: Public Sector Approach in Kenya
Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya KPA 2018 24-04-2018 Dr. Margaret Wainaina- Wafula Outline Introduction Evaluation of a child living with HIV. Standard
More informationTB Infection Control Policy. Scaling-up the implementation of collaborative TB/HIV activities in the Region of the
TB Infection Control Policy Scaling-up the implementation of collaborative TB/HIV activities in the Region of the Infection Control is aimed at minimizing the risk of TB transmission within populations
More informationClinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years. SAHIVCS - CME 13/06/15 DR.Henry Sunpath
Clinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years SAHIVCS - CME 13/06/15 DR.Henry Sunpath 1 Introduction What is new? Goals and objectives Guiding principles HIV continuum
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More information4 Management of Tuberculosis
4 Management of Tuberculosis and HIV Coinfection Clinical Protocol for the WHO European Region Edited by: Irina Eramova Srdan Matic Monique Munz HIV/AIDS TREATMENT AND CARE CLINICAL PROTOCOLS FOR THE WHO
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationTB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks
1 TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 2 Page 1 4 NHS Lothian Infection Prevention and Control Study Day On
More informationINH Preventive Therapy in. Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University
INH Preventive Therapy in Children Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University Prophylactic effect of INH on primary TB in
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationWorld Bank Training Program on HIV/AIDS Drugs
World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A Decision Maker s Guide to the Procurement of Medicines
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationIPT IMPLEMENTATION- SWAZILAND EXPERIENCE
IPT IMPLEMENTATION- SWAZILAND EXPERIENCE Gugu Mchunu-National TB/HIV coordinator Programmatic Management of Latent TB infection consultation meeting Seoul, Republic of Korea,27-28 APRIL,2016 TB Epidemiology
More informationWorld Health Organization HIV/TB Facts 2011
World Health Organization HIV/TB Facts 20 Note: The facts and figures of the HIV/TB Facts 20 are drawn from WHO HIV and TB surveillance data from 200 and 2009, as referenced below. Why is tuberculosis
More informationMANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS
MANAGEMENT OF TUBERCULOSIS IN NEONATES AND YOUNG INFANTS A Bekker FIDSSA Conference, 2017 OUTLINE Case Perinatal TB Approach to the TB-exposed newborn MOM AND BABY S Born by NVD at peripheral hospital
More informationClinical Vignette: Patient 1. Approach to Co-infection with TB. TB and HIV Co-infection: Some Resources. Objectives.
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb AETC Natl Resource Center: http://www.aidsetc.org Approach to Co-infection with TB and HIV: 2012 Henry Fraimow, MD Consultant, Southern N.J.
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationRevised Anti- Retroviral Treatment Guideline Update For Frontline Clinical Health Professionals 3/13/2013
Revised Anti- Retroviral Treatment Guideline Update For Frontline Clinical Health Professionals 3/13/2013 The following document highlights the changes National department of Health ARV treatment guidelines
More informationCLINICAL GUIDELINES: MANAGING COMMON COINFECTIONS AND COMORBIDITIES
CLINICAL GUIDELINES: MANAGING COMMON COINFECTIONS AND COMORBIDITIES 5 5.1 Introduction.... 192 5.2 Prevention, screening and management of common coinfections.... 192 5.3 Prevention, screening and management
More informationCLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More information